Infinity Pharmaceuticals, Inc. (INFI): Price and Financial Metrics
GET POWR RATINGS... FREE!
INFI POWR Grades
- INFI scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.02% of US stocks.
- The strongest trend for INFI is in Sentiment, which has been heading up over the past 179 days.
- INFI's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
INFI Stock Summary
- For INFI, its debt to operating expenses ratio is greater than that reported by merely 7.28% of US equities we're observing.
- With a price/sales ratio of 48.06, Infinity Pharmaceuticals Inc has a higher such ratio than 96.09% of stocks in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for INFI comes in at -99.48% -- higher than that of only 3.9% of stocks in our set.
- Stocks that are quantitatively similar to INFI, based on their financial statements, market capitalization, and price volatility, are SONN, ZSAN, BBI, ATNM, and DRRX.
- Visit INFI's SEC page to see the company's official filings. To visit the company's web site, go to www.infi.com.
INFI Valuation Summary
- INFI's price/sales ratio is 164.4; this is 4226.32% higher than that of the median Healthcare stock.
- INFI's price/sales ratio has moved up 161.7 over the prior 243 months.
- INFI's price/sales ratio has moved up 161.7 over the prior 243 months.
Below are key valuation metrics over time for INFI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INFI | 2021-08-31 | 164.4 | 7.6 | -7.3 | -5.2 |
| INFI | 2021-08-30 | 158.8 | 7.3 | -7.1 | -5.0 |
| INFI | 2021-08-27 | 164.4 | 7.6 | -7.3 | -5.2 |
| INFI | 2021-08-26 | 153.2 | 7.0 | -6.8 | -4.7 |
| INFI | 2021-08-25 | 160.6 | 7.4 | -7.1 | -5.1 |
| INFI | 2021-08-24 | 159.7 | 7.3 | -7.1 | -5.0 |
INFI Growth Metrics
- Its 3 year cash and equivalents growth rate is now at -54.13%.
- The 2 year price growth rate now stands at -51.44%.
- Its 5 year price growth rate is now at -81.43%.
The table below shows INFI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 1.843 | -39.41 | -44.21 |
| 2021-06-30 | 1.911 | -39.431 | -43.031 |
| 2021-03-31 | 1.759 | -37.432 | -41.235 |
| 2020-12-31 | 1.719 | -35.739 | -40.492 |
| 2020-09-30 | 1.592 | -36.104 | -41.275 |
| 2020-06-30 | 1.439 | -38.04 | -43.158 |
INFI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INFI has a Quality Grade of F, ranking ahead of 2.75% of graded US stocks.
- INFI's asset turnover comes in at 0.021 -- ranking 367th of 682 Pharmaceutical Products stocks.
- PALI, ATHX, and SIGA are the stocks whose asset turnover ratios are most correlated with INFI.
The table below shows INFI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.021 | 1 | 14.259 |
| 2021-06-30 | 0.025 | 1 | -11.302 |
| 2021-03-31 | 0.028 | 1 | -5.072 |
| 2020-12-31 | 0.036 | 1 | -2.864 |
| 2020-09-30 | 0.032 | 1 | -2.231 |
| 2020-06-30 | 0.027 | 1 | -2.017 |
INFI Price Target
For more insight on analysts targets of INFI, see our INFI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.29 | Average Broker Recommendation | 1.44 (Moderate Buy) |
INFI Stock Price Chart Interactive Chart >
INFI Price/Volume Stats
| Current price | $0.75 | 52-week high | $3.89 |
| Prev. close | $0.60 | 52-week low | $0.46 |
| Day low | $0.58 | Volume | 1,316,100 |
| Day high | $0.75 | Avg. volume | 881,453 |
| 50-day MA | $0.84 | Dividend yield | N/A |
| 200-day MA | $1.92 | Market Cap | 66.87M |
Infinity Pharmaceuticals, Inc. (INFI) Company Bio
Infinity Pharmaceuticals, Inc. discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company was founded in 2001 and is based in Cambridge, Massachusetts.
Latest INFI News From Around the Web
Below are the latest news stories about Infinity Pharmaceuticals Inc that investors may wish to consider to help them evaluate INFI as an investment opportunity.
Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat EstimatesIonis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?The big shareholder groups in Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) have power over the company. Institutions... |
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology ConferenceCAMBRIDGE, Mass., January 20, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET. The fireside chat will feature an interactive discussion with Infinity’s Executive Leadership Team, |
H.C. Wainwright Thinks Infinity Pharma’s Stock is Going to RecoverH.C. Wainwright analyst Michael King maintained a Buy rating on Infinity Pharma (INFI – Research Report) today and set a price target of $9.00. The company's shares closed last Wednesday at $1.77, close to its 52-week low of $1.48. According to TipRanks.com, King is a 4-star analyst with an average return of 17.6% and a 49.2% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Infinity Pharma is a Strong Buy with an average price target of $7.83, representing a 265.9% upside. |
Infinity to Present at 40th Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 06, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually. |
INFI Price Returns
| 1-mo | -6.53% |
| 3-mo | -33.63% |
| 6-mo | -65.60% |
| 1-year | -76.92% |
| 3-year | -48.63% |
| 5-year | -56.40% |
| YTD | -66.67% |
| 2021 | 6.13% |
| 2020 | 120.83% |
| 2019 | -18.64% |
| 2018 | -41.87% |
| 2017 | 50.37% |
Continue Researching INFI
Here are a few links from around the web to help you further your research on Infinity Pharmaceuticals Inc's stock as an investment opportunity:Infinity Pharmaceuticals Inc (INFI) Stock Price | Nasdaq
Infinity Pharmaceuticals Inc (INFI) Stock Quote, History and News - Yahoo Finance
Infinity Pharmaceuticals Inc (INFI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...